Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMTX Stock Forecast 2025-2026
$5.71
Current Price
$694.05M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IMTX Price Targets
+250.3%
To High Target of $20.00
+153.9%
To Median Target of $14.50
+57.6%
To Low Target of $9.00
IMTX Price Momentum
+6.1%
1 Week Change
-4.4%
1 Month Change
-51.4%
1 Year Change
-19.7%
Year-to-Date Change
-56.4%
From 52W High of $13.09
+73.0%
From 52W Low of $3.30
📊 TOP ANALYST CALLS
Did IMTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Immatics is one of their latest high-conviction picks.
Latest IMTX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, IMTX has a bullish consensus with a median price target of $14.50 (ranging from $9.00 to $20.00). Currently trading at $5.71, the median forecast implies a 153.9% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMTX Analyst Ratings
8
Buy
0
Hold
0
Sell
IMTX Price Target Range
Low
$9.00
Average
$14.50
High
$20.00
Current: $5.71
Latest IMTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2025 | Deutsche Bank | James Shin | Buy | Initiates | $10.00 |
| Apr 1, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Nov 19, 2024 | B of A Securities | Alex Stranahan | Buy | Maintains | $15.00 |
| Oct 7, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $19.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Sep 5, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| May 16, 2024 | Mizuho | Graig Suvannavejh | Buy | Maintains | $16.00 |
| Nov 2, 2023 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| Mar 31, 2023 | Mizuho | Graig Suvannavejh | Buy | Initiates | $12.00 |
| Mar 23, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| Aug 10, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $28.00 |
| Jun 3, 2022 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $26.00 |
| Mar 24, 2022 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $25.00 |
| Jul 15, 2021 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $27.00 |
| Mar 17, 2021 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $26.00 |
| Sep 22, 2020 | Goldman Sachs | Buy | Initiates | $0.00 | |
| Jul 27, 2020 | SVB Leerink | Outperform | Initiates | $0.00 | |
| Jul 24, 2020 | Jefferies | Buy | Initiates | $0.00 |
Immatics N.V. (IMTX) Competitors
The following stocks are similar to Immatics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immatics N.V. (IMTX) Financial Data
Immatics N.V. has a market capitalization of $694.05M with a P/E ratio of 26.8x. The company generates $169.67M in trailing twelve-month revenue with a -15.5% profit margin.
Revenue growth is -38.6% quarter-over-quarter, while maintaining an operating margin of -190.4% and return on equity of -4.8%.
Valuation Metrics
Market Cap
$694.05M
Enterprise Value
$151.33M
P/E Ratio
26.8x
PEG Ratio
-4.3x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
-38.6%
Gross Margin
N/A
Operating Margin
-190.4%
Net Margin
-15.5%
EPS Growth
-38.6%
Financial Health
Cash/Price Ratio
+78.4%
Current Ratio
10.3x
Debt/Equity
3.4x
ROE
-4.8%
ROA
-5.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Immatics N.V. (IMTX) Business Model
About Immatics N.V.
What They Do
Develops T-cell redirecting cancer immunotherapies.
Business Model
Immatics generates revenue through the discovery and development of innovative cancer immunotherapies that leverage the body's immune system. By focusing on personalized treatment approaches and unique cancer-specific targets, the company aims to establish partnerships and collaborations with other biotech firms and pharmaceutical companies, as well as through potential product sales and licensing agreements.
Additional Information
Headquartered in Tuebingen, Germany, with operations in Houston, Texas, Immatics is positioned as a key player in the biotechnology and immunotherapy sectors. The company utilizes proprietary platforms such as Xpresident and ACTengine to identify tumor-specific targets, contributing significantly to advancements in precision medicine and addressing the ongoing need for effective cancer treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
646
CEO
Dr. Harpreet Singh Ph.D.
Country
Germany
IPO Year
2018
Website
www.immatics.comImmatics N.V. (IMTX) Latest News & Analysis
Latest News
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
1 month ago
Quick Summary
Analysts' price targets for Immatics (IMTX) suggest a 174.5% upside. Consensus on raised earnings estimates indicates potential growth for the stock.
Why It Matters
Analysts' price targets suggesting a 174.5% upside for Immatics (IMTX) and consensus on earnings estimates signal potential growth, attracting investor interest despite past target inaccuracies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immatics N.V. reported positive results from its Phase 1b trial of IMA203 in metastatic melanoma, showing a 56% overall response rate and favorable tolerability. A Phase 3 trial, SUPRAME, is ongoing.
Why It Matters
Expanded data showing a 56% overall response rate and favorable tolerability for IMA203 in melanoma could signal strong potential for Immatics' stock growth and positive market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immatics N.V. (NASDAQ: IMTX) reported its business update and financial results for Q1 2025, focusing on T cell-redirecting cancer immunotherapies.
Why It Matters
Immatics' quarterly financial results and business update signal its progress in cancer immunotherapy, impacting investor sentiment and potential stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
2 months ago
Quick Summary
Immatics N.V. (NASDAQ: IMTX) will present its lead product, IMA203 TCR T-cell therapy targeting PRAME, at the ASCO Annual Meeting from May 30 to June 3, 2025, in Chicago.
Why It Matters
Immatics' presentation of IMA203 at ASCO could influence investor sentiment by showcasing potential advancements in cancer therapies, impacting stock performance and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immatics' IMA203 shows a 57% ORR in heavily pretreated patients, but faces toxicity concerns. The company has a $540M market cap, $628M cash, and negative enterprise value. Phase 3 data expected in early 2026.
Why It Matters
Immatics shows potential with IMA203's 57% ORR, but toxicity and long wait for Phase 3 data create uncertainty, impacting investor sentiment and valuation despite strong cash reserves.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Immatics N.V. (NASDAQ: IMTX) announced a business update and financial results for Q4 and full year 2024 on March 27, 2025, focusing on T cell-redirecting cancer immunotherapies.
Why It Matters
Immatics' financial results and business update signal its progress in cancer immunotherapy, influencing investor sentiment regarding growth potential and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IMTX Stock
What is Immatics N.V.'s (IMTX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Immatics N.V. (IMTX) has a median price target of $14.50. The highest price target is $20.00 and the lowest is $9.00.
Is IMTX stock a good investment in 2026?
According to current analyst ratings, IMTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMTX stock?
Wall Street analysts predict IMTX stock could reach $14.50 in the next 12 months. This represents a 153.9% increase from the current price of $5.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immatics N.V.'s business model?
Immatics generates revenue through the discovery and development of innovative cancer immunotherapies that leverage the body's immune system. By focusing on personalized treatment approaches and unique cancer-specific targets, the company aims to establish partnerships and collaborations with other biotech firms and pharmaceutical companies, as well as through potential product sales and licensing agreements.
What is the highest forecasted price for IMTX Immatics N.V.?
The highest price target for IMTX is $20.00 from at , which represents a 250.3% increase from the current price of $5.71.
What is the lowest forecasted price for IMTX Immatics N.V.?
The lowest price target for IMTX is $9.00 from at , which represents a 57.6% increase from the current price of $5.71.
What is the overall IMTX consensus from analysts for Immatics N.V.?
The overall analyst consensus for IMTX is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are IMTX stock price projections?
Stock price projections, including those for Immatics N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 5:38 PM UTC